Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:

Avacta Group Plc (AVCT.LN)

Avacta Group Plc (AVCT.LN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [LSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [LSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Full Chart

Fundamentals

See More
  • Market Capitalization, $K 150,121
  • Shares Outstanding, K 373,435
  • Annual Sales, $ 23,247 K
  • Annual Income, $ -24,947 K
  • EBIT $ N/A
  • EBITDA $ N/A
  • 60-Month Beta N/A
  • Price/Sales 5.36
  • Price/Cash Flow N/A
  • Price/Book 3.12
  • Price/Earnings ttm N/A
  • Earnings Per Share ttm -0.09
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date N/A
  • Annual Dividend & Yield N/A (N/A)
  • Most Recent Dividend N/A on N/A
  • Sector N/A
  • INDUSTRY GROUPING N/A

Price Performance

See More
Period Period Low Period High Performance
1-Month
31.050 +23.31%
on 03/04/25
44.480 -13.92%
on 03/19/25
-2.462 (-6.04%)
since 02/24/25
3-Month
31.050 +23.31%
on 03/04/25
60.400 -36.61%
on 01/06/25
-11.212 (-22.65%)
since 12/24/24
52-Week
31.050 +23.31%
on 03/04/25
86.400 -55.69%
on 07/11/24
-13.332 (-25.83%)
since 03/22/24
Free Barchart Webinars! Live educational sessions using site features to explore today's markets.

Most Recent Stories

More News
First Patient Dosed in the US in Avacta’s AVA6000 Phase 1 Clinical Study Business Wire - Thu Apr 27, 2023

Avacta Group plc (AIM: AVCT), a life sciences company developing innovative, targeted oncology drugs and powerful diagnostics, announces that the first patient has been dosed in the US under its Investigational...

AVCT.LN : 38.150 (-5.10%)
AVCT : 0.5980 (-11.01%)
Avacta Announces First Patient Dosed in Fifth Cohort of AVA6000 Phase Ia Dose Escalation Study Business Wire - Wed Apr 5, 2023

Avacta Group plc (AIM: AVCT), a life sciences company developing innovative, targeted oncology drugs and powerful diagnostics, announces that the first patient has been dosed in the fifth cohort of the...

AVCT.LN : 38.150 (-5.10%)
AVCT : 0.5980 (-11.01%)
Avacta Appoints Karen Harrison as Chief Operating Officer for Therapeutics Division Business Wire - Tue Mar 28, 2023

Avacta Group plc (AIM: AVCT), a life sciences company developing innovative, targeted oncology drugs and powerful diagnostics, today announced the appointment of Karen Harrison as Chief Operating Officer...

AVCT.LN : 38.150 (-5.10%)
AVCT : 0.5980 (-11.01%)
Avacta Announces AVA6000 Receives Orphan Drug Designation From the US Food and Drug Administration Business Wire - Mon Sep 5, 2022

Avacta Group plc (AIM: AVCT), a clinical stage oncology drug company and developer of powerful diagnostics based on its innovative Affimer ® and pre|CISION™ platforms, announces that the US Food and...

AVCT.LN : 38.150 (-5.10%)
AVCT : 0.5980 (-11.01%)
LG Chem Renews License Triggering Payment to Avacta Business Wire - Thu Jun 30, 2022

Avacta Group plc (AIM: AVCT), a clinical stage biopharmaceutical company developing innovative cancer therapies and powerful diagnostics based on its proprietary Affimer ® and pre|CISION™ platforms,...

AVCT.LN : 38.150 (-5.10%)
AVCT : 0.5980 (-11.01%)
Avacta Announces AffyXell Joint Venture Milestone and Increased Equity Stake Business Wire - Wed Apr 13, 2022

Avacta Group plc (AIM: AVCT), a clinical stage oncology drug company and developer of powerful diagnostics based on its innovative Affimer® and pre|CISION™ platforms, is pleased to announce that a milestone...

AVCT.LN : 38.150 (-5.10%)
AVCT : 0.5980 (-11.01%)
Avacta Appoints Dr Christina Coughlin as Non-Executive Director Business Wire - Mon Mar 21, 2022

Avacta Group plc (AIM: AVCT), a clinical stage biopharmaceutical company developing innovative cancer therapies and powerful diagnostics based on its proprietary Affimer® and pre|CISION™ platforms announces...

AVCT.LN : 38.150 (-5.10%)
AVCT : 0.5980 (-11.01%)
Avacta Selects Second pre|CISION™ Pro-drug Candidate for Development Business Wire - Tue Jan 18, 2022

Avacta Group plc (AIM: AVCT), a clinical stage biopharmaceutical company developing innovative cancer therapies and powerful diagnostics based on its proprietary Affimer® and pre|CISION™ platforms announces...

AVCT.LN : 38.150 (-5.10%)
AVCT : 0.5980 (-11.01%)
Avacta Announces AffiDX® SARS-CoV-2 Antigen Lateral Flow Test Receives CE Mark for Consumer Self-Testing Business Wire - Wed Dec 22, 2021

Avacta Group plc (AIM: AVCT), a clinical stage biopharmaceutical company developing innovative cancer therapies and powerful diagnostics based on its proprietary Affimer® and pre|CISION™ platforms,...

AVCT.LN : 38.150 (-5.10%)
AVCT : 0.5980 (-11.01%)
Avacta Announces AffiDx® SARS-CoV-2 Antigen Lateral Flow Test Detects the Omicron Variant Business Wire - Wed Dec 15, 2021

Avacta Group plc (AIM: AVCT), a clinical stage biopharmaceutical company developing innovative cancer therapies and powerful diagnostics based on its proprietary Affimer® and pre|CISION™ platforms is...

AVCT.LN : 38.150 (-5.10%)
AVCT : 0.5980 (-11.01%)
More news for this symbol

Barchart Technical Opinion

Strong sell

The Barchart Technical Opinion rating is a 100% Sell with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Key Turning Points

3rd Resistance Point 44.042
2nd Resistance Point 43.193
1st Resistance Point 41.697
Last Price 38.150
1st Support Level 39.352
2nd Support Level 38.503
3rd Support Level 37.007

See More

52-Week High 86.400
Fibonacci 61.8% 65.256
Fibonacci 50% 58.725
Fibonacci 38.2% 52.194
Last Price 38.150
52-Week Low 31.050

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot